(Corrects to add dropped word in headline)
(Reuters) – Bristol Myers Squibb said on Friday it would acquire Turning Point Therapeutics Inc for $4.1 billion in cash to gain access to its experimental cancer drug.
(The story corrects to add dropped word in headline.)
(Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel)
